These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 36404519)

  • 1. Correlation of Engraftment and Time from Melphalan Administration to Stem Cell Infusion.
    Shuman K; Palmer S; Anders B; Moore D; Ptachcinski J; Grgic T; Alexander M; Hill L; Sung AD; Armistead PM; Kennedy L; Shaw JR
    Transplant Cell Ther; 2023 Jan; 29(1):36.e1-36.e5. PubMed ID: 36404519
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Melphalan on day -1 versus day -2 in patients with plasma cell disorders undergoing autologous stem cell transplant.
    Watson AN; Shah SA; Shalhoub SD; Piedra KM; Komanduri KV; Kwon D; Pereira DL
    J Oncol Pharm Pract; 2023 Sep; 29(6):1398-1403. PubMed ID: 36245321
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD34+ hematopoietic progenitor cell dose as a predictor of engraftment and survival in multiple myeloma patients undergoing autologous stem cell transplantation.
    Aladağ Karakulak E; Demiroğlu H; Büyükaşik Y; Turgut M; Aksu S; Sayinalp N; Haznedaroğlu IC; Özcebe OI; Göker H
    Turk J Med Sci; 2020 Dec; 50(8):1851-1856. PubMed ID: 32512672
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differences in engraftment with day-1 compared with day-2 melphalan prior to stem cell infusion in myeloma patients receiving autologous stem cell transplant.
    Al Saleh AS; Sidiqi MH; Lee J; Dispenzieri A; Muchtar E; Buadi FK; Warsame R; Lacy MQ; Dingli D; Leung N; Gonsalves WI; Kapoor P; Kourelis TV; Skaer CA; Wittwer SK; Wolf RC; Hogan WJ; Kumar SK; Jacob E; Gertz MA
    Bone Marrow Transplant; 2020 Nov; 55(11):2132-2137. PubMed ID: 32358546
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of melphalan day -1 vs day -2 on outcomes after autologous stem cell transplant for multiple myeloma.
    Merino A; Shanley R; Rashid F; Langer J; Dolan M; Tu S; Jurdi NE; Rogosheske J; Hanna K; DeFor T; Janakiram M; Weisdorf D
    Front Immunol; 2024; 15():1310752. PubMed ID: 38504993
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of concurrent gabapentin or pregabalin with high-dose melphalan in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplant.
    Sivakumar A; Bryson EB; Hall KH; Maples KT; Goyal S; Joseph NS; Hofmeister CC; Kaufman JL; Lonial S; Nooka AK; Harvey RD
    Pharmacotherapy; 2022 Mar; 42(3):233-240. PubMed ID: 35122287
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness, Safety, and Cost Implications of Outpatient Autologous Hematopoietic Stem Cell Transplant for Multiple Myeloma.
    Marini J; Maldonado A; Weeda E; Neppalli A; Hashmi H; Edwards K
    Hematol Oncol Stem Cell Ther; 2023 May; 16(4):351-357. PubMed ID: 37363969
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of conditioning regimen toxicities among autologous stem cell transplantation eligible multiple myeloma patients: High-dose melphalan versus high-dose melphalan and bortezomib.
    Aypar E; İzzettin FV; Akı ŞZ; Sancar M; Yeğin ZA; Türköz-Sucak G
    J Oncol Pharm Pract; 2018 Jun; 24(4):281-289. PubMed ID: 29284356
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of High-Dose Propylene Glycol-Free Melphalan in Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation.
    Dhakal B; D'Souza A; Lakshman A; Hamadani M; Chhabra S; Thompson R; Shah N; Pasquini M; Hari P
    Biol Blood Marrow Transplant; 2018 Aug; 24(8):1610-1614. PubMed ID: 29751116
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Phase IIb, Multicenter, Open-Label, Safety, and Efficacy Study of High-Dose, Propylene Glycol-Free Melphalan Hydrochloride for Injection (EVOMELA) for Myeloablative Conditioning in Multiple Myeloma Patients Undergoing Autologous Transplantation.
    Hari P; Aljitawi OS; Arce-Lara C; Nath R; Callander N; Bhat G; Allen LF; Stockerl-Goldstein K
    Biol Blood Marrow Transplant; 2015 Dec; 21(12):2100-2105. PubMed ID: 26327631
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fractionated stem cell infusions for patients with plasma cell myeloma undergoing autologous hematopoietic cell transplantation.
    Landau H; Wood K; Chung DJ; Koehne G; Lendvai N; Hassoun H; Lesokhin A; Hoover E; Zheng J; Devlin SM; Giralt S
    Leuk Lymphoma; 2016 Aug; 57(8):1781-5. PubMed ID: 26758672
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Does Reinfusion of Stem Cell Products on Multiple Days Affect Engraftment?
    Solmaz Medeni Ş; Türkyılmaz D; Acar C; Sevindik ÖG; Yüksel F; Pişkin Ö; Özcan MA; Demirkan F; Ündar B; Alacacıoğlu İ; Özsan GH
    Turk J Haematol; 2018 Nov; 35(4):271-276. PubMed ID: 29923493
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sustained Hematopoietic Engraftment Potential after Prolonged Storage of Cryopreserved Hematopoietic Stem Cells Used in Salvage Autologous Stem Cell Transplantation.
    Makhani SS; Oza SP; Reich-Slotky R; Munshi PN; Biran N; Donato ML; Siegel DS; Vesole DH; Naam S; Rowley SD
    Transplant Cell Ther; 2022 Jun; 28(6):306.e1-306.e7. PubMed ID: 35248777
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluating the incidence of engraftment syndrome with different melphalan formulations in adult multiple myeloma and immunoglobulin light chain amyloidosis patients undergoing autologous hematopoietic cell transplantation.
    Kowalski KE; Wheeler SE; Adams CB; Voils SA; Richards AI
    J Oncol Pharm Pract; 2022 Mar; 28(2):274-281. PubMed ID: 33435822
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Impact of Renal Impairment in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation With Melphalan Conditioning.
    Ursu SG; Maples S; Williams KJ; Patrus G; Samhouri Y; Fazal S; Mewawalla P; Sadashiv S
    J Hematol; 2023 Oct; 12(5):201-207. PubMed ID: 37936977
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II Study of Propylene Glycol-Free Melphalan Combined with Carmustine, Etoposide, and Cytarabine for Myeloablative Conditioning in Lymphoma Patients Undergoing Autologous Stem Cell Transplantation.
    Cashen AF; Fletcher T; Ceriotti C; Gao F; Ghobadi A; Vij R; Stockerl-Goldstein K; DiPersio J; Abboud C
    Biol Blood Marrow Transplant; 2016 Dec; 22(12):2155-2158. PubMed ID: 27575541
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [High dose melphalan (HDM) is superior to cyclophosphamide plus etoposide and busulfan (CVB) as the conditioning regimen in autologous stem cell transplantation for multiple myeloma].
    Gu JL; Li J; Liu JR; Zou WY; Huang BH; Zheng D; Wang HH
    Zhonghua Xue Ye Xue Za Zhi; 2019 Sep; 40(9):732-737. PubMed ID: 31648473
    [No Abstract]   [Full Text] [Related]  

  • 18. CD34+ cell dose requirements for rapid engraftment in a sequential high-dose chemotherapy regimen of paclitaxel, melphalan, and cyclophosphamide, thiotepa, and carboplatin (CTCb) with PBPC support in metastatic breast cancer.
    Papadopoulos KP; Ayello J; Reiss RF; Troxel A; Kaufman E; Vahdat LT; Antman KH; Hesdorffer CS
    J Hematother Stem Cell Res; 1999 Aug; 8(4):357-63. PubMed ID: 10634173
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of Dose-Adjusted Melphalan in Obese Patients Undergoing Autologous Stem Cell Transplantation.
    Shultes KC; Arp C; Stockerl-Goldstein K; Trinkaus K; DeFrates S
    Biol Blood Marrow Transplant; 2018 Apr; 24(4):687-693. PubMed ID: 29225163
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Busulfan, Melphalan, and Bortezomib versus High-Dose Melphalan as a Conditioning Regimen for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma.
    Rodriguez TE; Hari P; Stiff PJ; Smith SE; Sterrenberg D; Vesole DH
    Biol Blood Marrow Transplant; 2016 Aug; 22(8):1391-1396. PubMed ID: 27164062
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.